| Papenburg and [[Patricia Fontela]] are co-Primary Investigators in the [[CATCO-Kids]] study, investigating the use of [[hydroxychloroquine]] in children with [[COVID-19]]. The trial is funded by the [[Montreal Children's Hospital Foundation]], and is a spinoff study from the [[CATCO]] trial, which is itself the Canadian branch of the [[SOLIDARITY Trial]].((//Funded Research.// COVID-19 Resources Canada. Retrieved April 19, 2022, from https://archive.ph/htYhS)) ((//Results of MI4 Emergency COVID-19 Research Funding.// (2021, August 23). McGill MI4. https://archive.ph/X6BWG)) Papenburg and Fontela are also both investigators for CATCO, including investigating [[remdesivir]].((Ali, K., Azher, T., Baqi, M., Binnie, A., Borgia, S., Carrier, F. M., Cavayas, Y. A., Chagnon, N., Cheng, M. P., Conly, J., Costiniuk, C., Daley, P., Daneman, N., Douglas, J., Downey, C., Duan, E., Duceppe, E., Durand, M., English, S., & Farjou, G. (2022). //Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.// CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, cmaj.211698. https://doi.org/10.1503/cmaj.211698)) | Papenburg and [[Patricia Fontela]] are co-Primary Investigators in the [[CATCO-Kids]] study, investigating the use of [[hydroxychloroquine]] in children with [[COVID-19]]. The trial is funded by the [[Montreal Children's Hospital Foundation]], and is a spinoff study from the [[CATCO]] trial, which is itself the Canadian branch of the [[SOLIDARITY Trial]].((//Funded Research.// COVID-19 Resources Canada. Retrieved April 19, 2022, from https://archive.ph/htYhS)) ((//Results of MI4 Emergency COVID-19 Research Funding.// (2021, August 23). McGill MI4. https://archive.ph/X6BWG)) Papenburg and Fontela are also both investigators for CATCO, including investigating [[remdesivir]].((Ali, K., Azher, T., Baqi, M., Binnie, A., Borgia, S., Carrier, F. M., Cavayas, Y. A., Chagnon, N., Cheng, M. P., Conly, J., Costiniuk, C., Daley, P., Daneman, N., Douglas, J., Downey, C., Duan, E., Duceppe, E., Durand, M., English, S., & Farjou, G. (2022). //Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.// CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, cmaj.211698. https://doi.org/10.1503/cmaj.211698)) |
| Papenburg is funded by a career award from [[Fonds de Recherche du Québec]], and funding from the [[Quebec Ministry of Health and Social Services]].((Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). //Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.// Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180)) He has received research funding from the [[CHUM Foundation]] and the [[Canadian Institutes of Health Research]] (CIHR). He has received grants from [[pharmaceutical_companies:MedImmune]] and [[pharmaceutical_companies:Sanofi]], as well as grants and personal fees from [[pharmaceutical_companies:AbbVie]], [[medical_technology_companies:Beckton Dickenson and Company|BD Diagnostics]], [[pharmaceutical_companies:Janssen]], and [[pharmaceutical_companies:Seegene]].((Papenburg, J., Mubareka, S., Allen, U. D., Skowronski, D., Stiver, H. G., Aoki, F. Y., & Evans, G. A. (2020). //Guidance on the use of antiviral agents for the 2019–2020 influenza season.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 5(2), 57–60. https://doi.org/10.3138/jammi.2020-01-13)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay.// medRxiv. Preprint. https://doi.org/10.1101/2021.01.23.21250325)) He has also received consulting fees from [[pharmaceutical_companies:Merck]], and personal fees from [[pharmaceutical_companies:Cepheid]] and [[pharmaceutical_companies:Roche]].((Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020). //Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2.// Annals of Internal Medicine, 172(11), 726–734. https://doi.org/10.7326/m20-1301)) ((Merckx, J., Cooke, S., El Tal, T., Bitnun, A., Morris, S. K., Yeh, E. A., Yea, C., Gill, P., Papenburg, J., Lefebvre, M.-A., Scuccimarri, R., Ulloa-Gutierrez, R., Brenes-Chacon, H., Yock-Corrales, A., Ivankovich-Escoto, G., Soriano-Fallas, A., Mezerville, M. H., Dewan, T., Restivo, L., & Nateghian, A. (2022). //Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study.// Canadian Medical Association Journal, 194(14), E513–E523. https://doi.org/10.1503/cmaj.210873)) He has also published research funded by the [[Janeway Children's Hospital Foundation]]. He also served on a Scientific Steering Committee for AbbVie.((Papenburg, J., & Harrison, R. (2021, October 27). //Seasonal Influenza Immunization 2021-2022.// National Collaborating Centre for Infectious Diseases. https://web.archive.org/web/20220419211302/https://nccid.ca/wp-content/uploads/sites/2/2021/12/DATAPOST-Rev-EN-Seasonal-Influenza-Webinar-2021-2022_Nov-23.LFpptm.pdf)) | Papenburg is funded by a career award from [[Fonds de Recherche du Québec]], and funding from the [[Quebec Ministry of Health and Social Services]].((Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). //Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.// Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180)) He has received research funding from the [[CHUM Foundation]] and the [[Canadian Institutes of Health Research]] (CIHR).((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) He has received grants from [[pharmaceutical_companies:MedImmune]] and [[pharmaceutical_companies:Sanofi]], as well as grants and personal fees from [[pharmaceutical_companies:AbbVie]], [[medical_technology_companies:Beckton Dickenson and Company|BD Diagnostics]], [[pharmaceutical_companies:Janssen]], and [[pharmaceutical_companies:Seegene]].((Papenburg, J., Mubareka, S., Allen, U. D., Skowronski, D., Stiver, H. G., Aoki, F. Y., & Evans, G. A. (2020). //Guidance on the use of antiviral agents for the 2019–2020 influenza season.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 5(2), 57–60. https://doi.org/10.3138/jammi.2020-01-13)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.// Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220)) ((Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). //Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay.// medRxiv. Preprint. https://doi.org/10.1101/2021.01.23.21250325)) He has also received consulting fees from [[pharmaceutical_companies:Merck]], and personal fees from [[pharmaceutical_companies:Cepheid]] and [[pharmaceutical_companies:Roche]].((Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020). //Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2.// Annals of Internal Medicine, 172(11), 726–734. https://doi.org/10.7326/m20-1301)) ((Merckx, J., Cooke, S., El Tal, T., Bitnun, A., Morris, S. K., Yeh, E. A., Yea, C., Gill, P., Papenburg, J., Lefebvre, M.-A., Scuccimarri, R., Ulloa-Gutierrez, R., Brenes-Chacon, H., Yock-Corrales, A., Ivankovich-Escoto, G., Soriano-Fallas, A., Mezerville, M. H., Dewan, T., Restivo, L., & Nateghian, A. (2022). //Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study.// Canadian Medical Association Journal, 194(14), E513–E523. https://doi.org/10.1503/cmaj.210873)) He has also published research funded by the [[Janeway Children's Hospital Foundation]]. He also served on a Scientific Steering Committee for AbbVie.((Papenburg, J., & Harrison, R. (2021, October 27). //Seasonal Influenza Immunization 2021-2022.// National Collaborating Centre for Infectious Diseases. https://web.archive.org/web/20220419211302/https://nccid.ca/wp-content/uploads/sites/2/2021/12/DATAPOST-Rev-EN-Seasonal-Influenza-Webinar-2021-2022_Nov-23.LFpptm.pdf)) |
